Prostate Cancer studies find advantage in daily acetaminophen and walks Brisk

POP a Tylenol and take a brisk walk for protection against prostate cancer? This is what the results of two new studies published this week suggested.

In the first study, published Monday in the journal Cancer Epidemiology, biomarkers and prevention, scientists have found that men who took a daily dose of acetaminophen (Tylenol) for five years had a 38% lower risk of developing cancer of the prostatecompared with men. In addition, daily acetaminophen has been associated with an of 51% reduced risk of developing an aggressive form of the disease. The men who took acetaminophen for less than five years saw no protective benefit.

Previous research has shown that taking aspirin or other drugs anti-inflammatory drugs (NSAIDs) every day can reduce the risk of prostate cancer. The authors believe that the same may be true of acetaminophen; While not an NSAID, it has anti-inflammatory properties.

For the study, researchers looked at data 78,485 men who participated in the longitudinal Cancer Prevention study II Nutrition cohort, answering questions on the use of food and pharmaceutical plan every two years from 1992. During the period of follow-up, there were 8,092 cases of prostate cancer - much less in the group who took acetaminophen daily for five years.

The second study, published Tuesday online research on Cancer, involved 1,455 men who had already been achieved in prostate cancer stage. Researchers at the University of California, San Francisco (UCSF) and Harvard School of Public Health, then the men from 2004 to 2009 and found that those who engaged in regular brisk walking after diagnosis were significantly less likely to see their progression of the disease.

Men who walked fast - at a rate of approximately 3 miles per hour or faster - at least three hours per week were 57% less likely to experience of the progression of the disease (including high levels of PSA)(, secondary treatment of bone metastases and prostate cancer-related deaths), compared with men who walked less and more slowly.

"The important point is the intensity of activity," Erin Richman, a postdoctoral fellow at UCSF, said in a statement. "The March must be rapid for men to experience an advantage."

Researchers have said that the effect of speed walking remains independent of age, diagnosis, type of treatment and characteristics of the disease. Average age of patients at diagnosis was 65. The findings are consistent with previous research, which suggests that physical activity can help reduce the risk of deaths from the disease in some cases of prostate cancer.

Why the association? Reports MedPage Today:

Richman and his colleagues have noted that brisk walking may reduce resistance to insulin, which reduces bioavailable,-1 (IGF1) insulin-like growth factor and increases adiponectin levels, which are all associated with the decrease in the risk of prostate cancer advanced or fatal in vitro and in vivo.

Another potential source of reduction is inflammation reduced due to low circulation of Interleukin-6, high levels of which "predicts risk of 73% increased to die of cancer of the prostate in men of normal weight."wrote the researchers.

Prostate cancer is the second leading cause of cancer death in men. According to the National Cancer Institute, men about 32,050 die of cancer of the prostate in 2010 and 217,000 new cases were diagnosed. More than 2.2 million of men to the United States with prostate cancer.

Less made mammograms, studies show

Mammograms for women in their forties, they may be in decline.Doctors less advising test for women in their forties study findsFewer these patients is projected, it reportsChange came after the recommendations of the Advisory Council

 the use of mammography has plunged since a medical working group made controversial recommendations that women in their forties, they may not need to get breast cancer projections, each year one of the three studies on small scale which will be presented Monday.

Studies related to this subject will be presented at the annual meeting of the American Roentgen Ray Society. They do not appear in journals.

Studies suggest that less than doctors recommend annual mammograms for women in quarantine their, fewer patients in this age group are get planned and that routine mammography tumors are more likely to be detected in the early stages of cancer.

The studies examined the impact of the controversial guidelines issued by the U.S. Preventive Services Task Force, a Federal Advisory Board.

Who decides on mammograms? Inside of the task force

In November 2009, the group said that annual mammograms should not be automatic at the age of 40 years and that doctors should discuss their risks and benefits with their patients. He recommended that projections of routine mammography every two years to the ages of 50 and 74 women.

"The advantage among women 40 to 49 years is small enough, said Dr. Virginia Moyer, President of the task force, on the annual mammograms." There is a real, but rather modest advantage. There are also risks, and they are higher in women younger than older women.

Mammograms are less efficient to detect growths in young women, whose breasts are perhaps more dense. Screening improves with older women, because breast tissue change over time.

As a result, some women experience false positive, anxiety and unnecessary biopsies by mammography, according to the data. About 15% of women in their forties, their detect cancer of the breast by mammography.

I should get a mammogram?

"The benefit is modest enough, it must be an individual decision," Moyer said about mammography for women, in the quarantine their. "."

This Council contradicted cancer groups such as the American Cancer Society and Susan g. Komen, who said women 40 to find a cure, and beaver to get checked every year. It sparked an immediate outcry from these groups and cancer survivors, who say mammograms of younger women routine that 50 can save lives.

Breast cancer rates U.S. ounce-dropping now stable

Suspicious vintage captured in regular screening mammography is more likely to be in the early stages and therefore more treatable, said Dr. Donna Plecha, head of the division of mammography in the hospitals of the University Medical Center of cases in Ohio.

Reviewing records of 524 biopsies (samples of suspicious growths in the breasts) by women in their forties, their in 2008-2009 to his hospital.

359 Biopsies of patients in screening mammography, 15% had cancer. These cancers were more manageable because they were captured in the previous steps, said Plecha.

Although 85% of these biopsies is found to be carrying some "can show us that the patient is at higher risk of breast cancer," she said.

"I have not met many patients who do not appreciate us be thorough, to try to find cancers at an early stage," said Plecha. "I recommend always from the age of 40 years, the screening mammography" because captured cancers earlier would be more curable.

ID of breast cancer would be more precisely by docs who see analyses more

The Plecha findings were not surprising of Moyer. It is clear that the annual projections would include cancers before they progress, she said.

The study assumes that catch the first steps for women 40-49 years would result in fewer breast cancer deaths.

"The data we have suggest that 1 mile will benefit from mammography in the age of 40-49," she said. "There are many set of assumptions that are not supported by the data, that they presented".

The Working Group did not say do not get mammograms, said Moyer.

"It might make women want to get the test", she said. "This is a decision that should belong to the woman with appropriate share info."

In another study, Dr. Lara Hardesty, head of the section of the breast imaging at the University of Colorado hospital, examined the results of the investigation of less than 50 internists, gynecologists, family physicians and nurse-midwives.

She found that clinicians less were recommending mammograms annual after working group guidelines have been issued.

Before the guidelines, 56% recommended mammograms for women in the range of 40 to 49 years. After the guidelines, this rate has decreased by 20% and 56% of clinicians reported that they discussed the risks and benefits of screening to patients. This decline, Hardesty said, "is a statistically significant difference", but it also showed that more doctors were discussing mammograms with patients.

Also, Hardesty concluded that there is 205 mammograms less among women in their forties, their after the guidelines were issued. In patients 50 and older, mammograms increased slightly 4,479 patients to the inhabitants.

It was not known why mammograms in 40s decreased as mammograms of older women increased slightly.

Hardesty offered this hypothesis: older women are used to have annual mammograms because they have for years. During this time, younger women may feel as if they do not get this screening.

Although the Working Group concluded that the net benefit of mammography in quarantine is small, Hardesty said: "If you are the only person find us your cancer, it is the world to you".

FDA orders for certain asthma drugs (Reuters) security studies

U.S. health regulators have ordered cash to conduct clinical trials involving a total of 53,000 patients to test the safety of a class controversial inhaled asthma drugs that are already on the market.

The trials are required to demonstrate the safety of the drugs known as beta-agonists to long duration of action (LABAs) when used in combination with inhaled steroids, another class of drugs against asthma, the U.S. Food and Drug Administration, said Friday.

Studied LABAs are AstraZeneca Symbicort, Advair Diskus of GlaxoSmithKline, Merck & Dulera of Co and Foradil of Novartis AG.

LABAs since long the object of FDA as they may increase the risk of seriously worsening asthma symptoms which can lead to hospitalization and death.

The drugs work by relaxing the muscles of the airway to help people breathe and are also used to treat the condition of severe lung, chronic obstructive pulmonary disease

(COPD).

The FDA expects to receive results in 2017 for studies that will begin later this year.

In four of the tests requested by the FDA, each of the LABAs more a corticosteroid is compared with the single steroids in patients 12 years of age and over. These studies should include a total of patients group.

Some of these drugs. as Advair and Symbicort, are combination therapies that include a LABA with a corticosteroid.

The Agency also requested a trial of 6 200 patients more young, aged 4 to 11, using Advair Diskus of Glaxo.

The enormous size of the studies reported that the FDA wants to be completely safe on the safety profile of these drugs, they are used so widely, analyst for Morningstar Damien Conover.

A large study population could pose some financial challenges for cash, he said.

"Glaxo complies with the request of the FDA to implement the study of Phase 4," Glaxo spokesman Lisa Behrens, said the trial of pharmacovigilance.

AstraZeneca said it completed the study efforts Agency and media protocol for addressing questions about the use of the drug.

Novartis said that it was reviewing the requirements issued by the FDA postmarketing surveillance while Merck said that it would have little time a comment.

The FDA issued last June of warnings on LABAs, saying that they should never be used on their own to treat asthma and requested cash to conduct further studies to better understand the safety of the LABAs when used with steroids inhalation.

The Agency has posted the requirements of the study on its Web site at http://www.fda.gov/Drugs/DrugSafety/ucm251512.htm.